Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review

@article{Shimon2012PituitarydirectedMT,
  title={Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review},
  author={Ilan Shimon and Liat Rot and Edna Inbar},
  journal={Pituitary},
  year={2012},
  volume={15},
  pages={608-613}
}
Hypercortisolism due to an ACTH-secreting pituitary adenoma (Cushing’s disease) is a chronic condition associated with high morbidity and mortality if inadequately managed. Pasireotide is a multireceptor-targeted somatostatin analogue and is the only approved medical therapy for Cushing’s disease that treats the underlying cause of the disorder. This paper reviews the available literature for medical-therapy-induced adenoma volume reduction in patients with Cushing’s disease and reports the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

adrenal-blocking drugs and ketaconazole

  • RA Feelders, LJ Hofland, syndrome de Herder WW Medical treatment of Cushing’s
  • Neuroendocrinology 92(Suppl 1):111–115 Pituitary
  • 2012
1 Excerpt

Mechanism and management of hyperglycemia associated with pasireotide: Results from studies in healthy volunteers

  • RR Henry, S Mudaliar, K Wetli-Hermosillo, M Ligueros-Saylan, S Chenji, G Golor
  • Endocr Rev 32(03),
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…